ADMA Biologics Inc. [NASDAQ: ADMA] price plunged by -1.32 percent to reach at -$0.03. The company report on September 9, 2020 that ADMA Biologics to Participate in Morgan Stanley Virtual Healthcare Conference.
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Virtual Healthcare Conference on Monday, September 14, 2020, at 4:30 p.m. ET.
A webcast of the event will be available on the Company’s website at https://ir.admabiologics.com/events-webcasts and will be archived for 90 days following the event.
A sum of 2288624 shares traded at recent session while its average daily volume was at 6.33M shares. ADMA Biologics Inc. shares reached a high of $2.335 and dropped to a low of $2.21 until finishing in the latest session at $2.24.
The average equity rating for ADMA stock is currently 1.70, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on ADMA Biologics Inc. [ADMA]:
Jefferies have made an estimate for ADMA Biologics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 04, 2019. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price from $10 to $13. The new note on the price target was released on April 15, 2019, representing the official price target for ADMA Biologics Inc. stock. Previously, the target price had yet another raise to $10, while H.C. Wainwright analysts kept a Buy rating on ADMA stock. On December 11, 2017, analysts decreased their price target for ADMA shares from 13 to 8.
The Average True Range (ATR) for ADMA Biologics Inc. is set at 0.16, with the Price to Sales ratio for ADMA stock in the period of the last 12 months amounting to 5.36. The Price to Book ratio for the last quarter was 2.52, with the Price to Cash per share for the same quarter was set at 0.85.
ADMA Stock Performance Analysis:
ADMA Biologics Inc. [ADMA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -7.44. With this latest performance, ADMA shares dropped by -5.88% in over the last four-week period, additionally sinking by -16.10% over the last 6 months – not to mention a drop of -50.00% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ADMA stock in for the last two-week period is set at 42.84, with the RSI for the last a single of trading hit 40.01, and the three-weeks RSI is set at 43.88 for ADMA Biologics Inc. [ADMA]. The present Moving Average for the last 50 days of trading for this stock 2.49, while it was recorded at 2.31 for the last single week of trading, and 2.97 for the last 200 days.
Insight into ADMA Biologics Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and ADMA Biologics Inc. [ADMA] shares currently have an operating margin of -141.14 and a Gross Margin at -37.48. ADMA Biologics Inc.’s Net Margin is presently recorded at -164.50.
Return on Total Capital for ADMA is now -47.36, given the latest momentum, and Return on Invested Capital for the company is -55.28. Return on Equity for this stock declined to -210.08, with Return on Assets sitting at -44.71. When it comes to the capital structure of this company, ADMA Biologics Inc. [ADMA] has a Total Debt to Total Equity ratio set at 323.48. Additionally, ADMA Total Debt to Total Capital is recorded at 76.39, with Total Debt to Total Assets ending up at 66.67. Long-Term Debt to Equity for the company is recorded at 322.61, with the Long-Term Debt to Total Capital now at 76.18.
Reflecting on the efficiency of the workforce at the company, ADMA Biologics Inc. [ADMA] managed to generate an average of -$153,756 per employee. Receivables Turnover for the company is 12.07 with a Total Asset Turnover recorded at a value of 0.27.ADMA Biologics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.80 and a Current Ratio set at 11.10.
ADMA Stock EPS
With the latest financial reports released by the company, ADMA Biologics Inc. posted -0.19/share EPS, while the average EPS was predicted by analysts to be reported at -0.23/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 17.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ADMA.
ADMA Biologics Inc. [ADMA] Insider Position Details
There are presently around $109 million, or 62.10% of ADMA stock, in the hands of institutional investors. The top three institutional holders of ADMA stocks are: PERCEPTIVE ADVISORS LLC with ownership of 16,584,802, which is approximately 0% of the company’s market cap and around 0.70% of the total institutional ownership; BLACKROCK INC., holding 5,721,937 shares of the stock with an approximate value of $12.99 million in ADMA stocks shares; and VANGUARD GROUP INC, currently with $7.97 million in ADMA stock with ownership of nearly -1.333% of the company’s market capitalization.
Positions in ADMA Biologics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 55 institutional holders increased their position in ADMA Biologics Inc. [NASDAQ:ADMA] by around 4,235,540 shares. Additionally, 46 investors decreased positions by around 4,308,652 shares, while 14 investors held positions by with 40,294,426 shares. The mentioned changes placed institutional holdings at 48,838,618 shares, according to the latest SEC report filing. ADMA stock had 21 new institutional investments in for a total of 1,591,853 shares, while 18 institutional investors sold positions of 2,026,666 shares during the same period.